At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
Abemaciclibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
In Brief
A Phase 2 clinical trial evaluating Abemaciclib for Metastatic Castration-Resistant Prostate Cancer. Completed, enrolled 44 participants across 14 sites in 3 countries.
Detailed Summary
The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJan 2021
Primary CompletionApr 2022
Study CompletionJun 2023
TodayJul 2026
First PostedMay 29, 2020
Enrollment StartJan 20, 2021
Primary CompletionApr 27, 2022
Study CompletionJun 2, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.1 years ago
Interventions
Abemaciclibdrug
Administered orally